Need Help?
Copied to clipboard!

Longitudinal profiling of ASPSCR1-TFE3 Type 2 Alveolar Soft Part Sarcoma unveils therapeutic targets

Alveolar soft part sarcoma (ASPS) is a rare, highly metastatic soft tissue sarcoma primarily managed through surgery and adjuvant radiotherapy. Discovery of novel treatments is hindered by a scarcity of models to identify genomic vulnerabilities to formulate effective therapeutic trials. We established the first patient-derived xenograft and corresponding cell line from a patient with ASPSCR1-TFE3 Type 2 fusion-positive ASPS. Longitudinal whole genome sequencing, phospho-proteomics, RNA sequencing and drug screening were used to characterize the mutational and clonal landscape of disease progression and identify therapeutic options. ASPSCR1-TFE3 Type 2 fusion expression revealed transcriptional targets including surface proteins such as GPNMB that are being developed for immune- based therapies. Drug screening identified proteasome inhibition as a therapeutic vulnerability and was supported by an upregulation of the ubiquitin-proteasome system in ASPS compared to other solid pediatric cancers. Clinically approved proteasome inhibitors bortezomib and carfilzomib confirmed nanomolar efficacy in vitro and significant tumor inhibition in vivo. Emerging clinical interest within the pediatric and adolescent populations creates an opportunity for evaluation in this rare pediatric population.

Cite

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD50000003068 Illumina NovaSeq 6000 Illumina NovaSeq X Plus NextSeq 2000 43